Aim Immunotech Inc (AIM)
$0.33
Performance
- $0.31$0.33$0.33
6.97%
Downside
Day's Volatility :7.03%
Upside
0.06%
- $0.25$0.68$0.33
23.91%
Downside
52 Weeks Volatility :63.07%
Upside
51.47%
Returns
| Period | Aim Immunotech Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -22.82% | 0.0% |
6 Months | -14.58% | 0.0% |
1 Year | -45.79% | 0.0% |
3 Years | -83.84% | -22.3% |
Highlights
Market Capitalization | 18.9M |
Book Value | $0.11 |
Earnings Per Share (EPS) | -0.56 |
Wall Street Target Price | 3.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -7388.0% |
Return On Assets TTM | -80.04% |
Return On Equity TTM | -154.79% |
Revenue TTM | 201.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 19.0% |
Gross Profit TTM | -715.0K |
EBITDA | -31.4M |
Diluted Eps TTM | -0.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.39 |
EPS Estimate Next Year | -0.44 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.12 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 960.61%
Technicals Summary
Sell
Neutral
Buy
Aim Immunotech Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aim Immunotech Inc | 3.86% | -14.58% | -45.79% | -83.84% | -83.68% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aim Immunotech Inc | NA | NA | NA | -0.39 | -1.55 | -0.8 | NA | 0.11 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aim Immunotech Inc | Buy | $18.9M | -83.68% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Aim Immunotech Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 40.0K → 50.0K (in $), with an average increase of 20.0% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -12.57M → -1.83M (in $), with an average increase of 111.0% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 82.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 153.0%
Company Information
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
Organization | Aim Immunotech Inc |
Employees | 26 |
CEO | Mr. Thomas K. Equels Esq., J.D., M.S. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$0.33
-0.94%
Keyarch Acquisition Corp
$0.33
-0.94%
Connexa Sports Technologies Inc
$0.33
-0.94%
Us Value Etf
$0.33
-0.94%
First Wave Biopharma Inc
$0.33
-0.94%
Global X Msci Next Emerging
$0.33
-0.94%
Fat Projects Acquisition Corp
$0.33
-0.94%
Capital Link Global Fintech
$0.33
-0.94%
Applied Uv Inc
$0.33
-0.94%